Xeris Biopharma Holdings Inc (NASDAQ: XERS) flaunted slowness of -3.41% at $1.70, before settling in for the price of $1.76 at the close. Taking a more long-term approach, XERS posted a 52-week range of $1.46-$3.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 195.35%. Meanwhile, its Annual Earning per share during the time was 38.13%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 23.17%. This publicly-traded company’s shares outstanding now amounts to $138.13 million, simultaneously with a float of $125.56 million. The organization now has a market capitalization sitting at $238.77 million. At the time of writing, stock’s 50-day Moving Average stood at $2.3435, while the 200-day Moving Average is $2.1998.
Xeris Biopharma Holdings Inc (XERS) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Xeris Biopharma Holdings Inc industry. Xeris Biopharma Holdings Inc’s current insider ownership accounts for 10.60%, in contrast to 40.99% institutional ownership. According to the most recent insider trade that took place on Mar 14 ’24, this organization’s Director bought 4,500 shares at the rate of 2.16, making the entire transaction reach 9,720 in total value, affecting insider ownership by 11,000. Preceding that transaction, on Nov 27 ’23, Company’s Director bought 5,400 for 1.87, making the whole transaction’s value amount to 10,098. This particular insider is now the holder of 5,400 in total.
Xeris Biopharma Holdings Inc (XERS) Earnings and Revenue Records
Going through the last 3-months fiscal report unveiled on the 12/31/2023, it has been observed that the corporation posted -0.12 earnings per share (EPS) during the time that was better the consensus figure (set at -0.17) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
Xeris Biopharma Holdings Inc’s EPS increase for this current 12-month fiscal period is 23.17% and is forecasted to reach -0.15 in the upcoming year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Let’s observe the current performance indicators for Xeris Biopharma Holdings Inc (XERS). It’s Quick Ratio in the last reported quarter now stands at 1.23. The Stock has managed to achieve an average true range (ATR) of 0.11. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.46.
In the same vein, XERS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.45, a figure that is expected to reach -0.11 in the next quarter, and analysts are predicting that it will be -0.15 at the market close of one year from today.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Now, what If we examine the latest scores posted by [Xeris Biopharma Holdings Inc, XERS]. During the last 5-days, its volume was lower the volume of 2.13 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 16.26% While, its Average True Range was 0.0989.
Raw Stochastic average of Xeris Biopharma Holdings Inc (XERS) in the period of the previous 100 days is set at 0.64%, which indicates a major fall in contrast to 2.67% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 33.08% that was lower than 71.60% volatility it exhibited in the past 100-days period.
